Healthcare
Live Price
Offline$4.70
-12.15% today
1Y Change
-28.93%
Window
Jun 23, 2025 β Jun 12, 2026
Coverage: 245 bars Β· Jun 23, 2025 β Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TransCode Therapeutics, Inc. (RNAZ) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $4.70 and down 28.9% across the available one-year price window (Jun 23, 2025 β Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -11.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -11.6%, free cash flow -46.2% with operating margin 0.0% and ROIC -17.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RNAZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNAZ
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
RNAZ Max Drawdown
-67.30%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Uses the longest available daily history for RNAZ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.3M
+65.7% YoY
Free Cash Flow
-$493.0K
+91.1% YoY
Revenue Growth
+0.0%
EPS Growth
-11.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -535K | -517K | -99K | -42K | 0 |
| Operating Income | -16M | -19M | -19M | -6M | -727K |
| EBITDA | -16M | -18M | -17M | -7M | -2M |
| Net Income | -17M | -19M | -18M | -7M | -2M |
| EPS (Diluted) | β | β | β | β | β |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6M | 3M | 5M | 21M | 828K |
| Total Assets | 7M | 5M | 8M | 23M | 1M |
| Total Liabilities | 9M | 4M | 4M | 3M | 4M |
| Shareholder Equity | -2M | 2M | 3M | 20M | -3M |
| Total Debt | 38K | 451K | 0 | 0 | 2M |
| Net Debt | -6M | -2M | -5M | -21M | 1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
493K
+90.6% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
493K
+91.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-491.6%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.